ABSTRACT
We describe a recent case of Stevens-Johnson Syndrome. A 49-year-old man was admitted to the Intensive Care Unit of an Anaesthesia and Resuscitation Department because of a Fournier gangrene that derived in a sepsis, ventilator-associated pneumonia, and renal failure. He was under treatment with cefepime and suffered a generalized status epilepticus, so started treatment with phenytoin. The next day he developed a "maculous cutaneous eruption in trunk and lower limbs" compatible with a Stevens-Johnson Syndrome. Stevens-Johnson Syndrome is a very severe and potentially fatal multiorganic disease, especially when present in critically ill patients, with a strong drug-related etiology, especially with antiepileptic drugs.
Subject(s)
Anti-Bacterial Agents/adverse effects , Anticonvulsants/adverse effects , Cephalosporins/adverse effects , Phenytoin/adverse effects , Stevens-Johnson Syndrome/therapy , Anticonvulsants/therapeutic use , Cefepime , Critical Illness , Fournier Gangrene/complications , Fournier Gangrene/drug therapy , Humans , Kidney Failure, Chronic/complications , Male , Middle Aged , Phenytoin/therapeutic use , Pneumonia, Ventilator-Associated/complications , Pneumonia, Ventilator-Associated/drug therapy , Sepsis/complications , Sepsis/drug therapy , Status Epilepticus/chemically induced , Status Epilepticus/drug therapy , Stevens-Johnson Syndrome/etiologyABSTRACT
OBJECTIVE: To describe a recent case of suspected interaction between oral cyclosporine modified and iron. CASE SUMMARY: A 33-year-old man underwent urgent cardiac transplantation for refractory cardiogenic shock caused by acute myocarditis. The patient had persistently low levels of cyclosporine despite a dose increase of the drug after the change of administration route from intravenous to oral. Spacing the administration of cyclosporine modified from oral iron resolved the problem. This drug interaction was reported as "probable" as determined by a Drug Interaction Probability Scale score of 7. Using this scoring system, the patient experienced a probable drug interaction between cyclosporine and iron both administered orally, and we surmise that the mechanism is that iron physicochemically destabilizes the cyclosporine microemulsion when both are administered concurrently. DISCUSSION: This may be because of the interaction between cyclosporine microemulsion and iron because this cation can destabilize the immunosuppressant dosage form. CONCLUSIONS: Taking into account that joint administration of oral iron and cyclosporine modified can generate a physicochemical interaction that involves a decrease in the absorption of cyclosporine modified, we believe that it is necessary to recommend spacing administrations of both drugs as well as monitoring levels of cyclosporine in order to ensure optimal levels of immunosuppression.
ABSTRACT
Manual en el que a través de casos clínicos se aborda la farmacoterapia de enfermedades con baja prevalencia, que disponen de tratamientos huérfanos y que afectan a pacientes de Castilla-La Mancha. Incluye diversas patologías como la enfermedad de Behcet, de Fabry, de Menkes, de Pompe, de Wilson, hemoglobinuria paroxística nocturna, mielofibrosis idiopática, tirosinemia, trombocitopenia inmune primaria y defectos del Ciclo de la Urea.
